American Water's Q3 Cost-Driven Miss Confirms Wait Thesis

What happened

American Water's third-quarter earnings fell short of consensus estimates as rising operating costs offset revenue growth, affirming the persistent cost inflation flagged in prior reports. The miss occurred despite management's emphasis on rate hikes and acquisitions supporting the longer-term outlook, indicating that regulatory recovery continues to lag expense increases. This outcome aligns with the deep value master report's identification of O&M as a dominant near-term headwind. The pending all-stock merger with Essential Utilities remains a binary catalyst, with multi-state regulatory approvals still unresolved and potentially value-destructive conditions possible. The combination of weak earnings execution and unresolved deal risk reinforces the existing WAIT rating and the need for observable cost control before any constructive position.

Implication

The short-term implication is to avoid adding to positions until AWK demonstrates that operating expense inflation is moderating and rate mechanisms are catching up with costs. Monitor upcoming regulatory proceedings for the Essential Utilities merger, as any conditions deemed 'burdensome' would further pressure the equity. The attractive entry zone remains near $120, and the stock should only be considered if it falls toward that level or if there is clear evidence of cleaner regulatory approvals. Conversely, if cost pressures intensify or the merger timeline slips, the bear case value of $115 becomes more probable. Maintain the WAIT rating and re-assess within six to twelve months based on docket milestones and quarterly cost trends.

Thesis delta

The earnings miss reinforces the core thesis concern about operating cost inflation and its impact on adjusted EPS, but does not fundamentally alter the investment stance. The WAIT rating is unchanged, and the attractive entry point remains near $120 with a trim level around $150. Confidence in management's near-term execution is slightly reduced, though the long-term story still hinges on regulatory approval outcomes and cost recovery.